Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients.

[1]  J. Tuomilehto,et al.  Gemfibrozil in the treatment of dyslipidaemia. A 5-year follow-up study. , 2009, Acta medica Scandinavica. Supplementum.

[2]  W. Koenig,et al.  Seasonal variations of rheological and hemostatic parameters and acute-phase reactants in young, healthy subjects. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[3]  M. Nieminen,et al.  Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.

[4]  W. Sheu,et al.  Gemfibrozil treatment of hypertriglyceridemia: improvement on fibrinolysis without change of insulin resistance. , 1997, American heart journal.

[5]  L. Hamann,et al.  Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists , 1997, Nature.

[6]  H. Ronday,et al.  Progress in clinical fibrinolysis , 1997 .

[7]  C. Bode,et al.  Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors. , 1997, Circulation.

[8]  J. Auwerx,et al.  The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). , 1997, Biochimie.

[9]  P. Demacker,et al.  On the presumed inaccuracy of the Friedewald formula in hypertriglyceridemic plasma: a role for imprecise analysis? , 1996, Clinical chemistry.

[10]  A. Asplund-Carlson.  Effects of Gemfibrozil Therapy on Glucose Tolerance, Insulin Sensitivity and Plasma Plasminogen Activator Inhibitor Activity in Hypertriglyceridaemia , 1996, Journal of cardiovascular risk.

[11]  P. Hjemdahl,et al.  Gemfibrozil Reduces Thrombin Generation in Patients with Combined Hyperlipidaemia, without Influencing Plasma Fibrinogen, Fibrin Gel Structure or Coagulation Factor VII , 1996, Thrombosis and Haemostasis.

[12]  W. Sheu,et al.  Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations. , 1996, The Journal of clinical endocrinology and metabolism.

[13]  D. Baldassarre,et al.  Plasminogen activator inhibitor type 1 secretion by HepG2 cells: opposite effects of two fibric acid derivatives. , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[14]  M. Alessi,et al.  Fibrinolysis and risk of coronary artery disease , 1996 .

[15]  J Auwerx,et al.  Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. , 1996, Journal of lipid research.

[16]  P. Hjemdahl,et al.  Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[17]  L. Tenkanen,et al.  Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. , 1995, Circulation.

[18]  B. Wiman.  Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma: Its Role in Thrombotic Disease , 1995, Thrombosis and Haemostasis.

[19]  A. Hamsten,et al.  5 Fibrinolysis and atherosclerosis , 1995 .

[20]  M. Blombäck,et al.  Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[21]  M. Taskinen,et al.  Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. , 1995, Metabolism: clinical and experimental.

[22]  M. Ohrvall,et al.  A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. , 1995, Metabolism: clinical and experimental.

[23]  A. Avogaro,et al.  Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients. , 1995, Atherosclerosis.

[24]  I. Juhan-vague,et al.  Insulin resistance and alterations in the fibrinolytic system , 1993 .

[25]  G. Avellone,et al.  Fibrinolytic Effect of Gemfibrozil Versus Placebo Administration in Response to Venous Occlusion , 1993 .

[26]  B. Sobel,et al.  Inhibition of Endothelial Cell Expression of Plasminogen Activator Inhibitor Type-1 by Gemfibrozil , 1993, Thrombosis and Haemostasis.

[27]  E. Ernst,et al.  Fibrinogen as a Cardiovascular Risk Factor , 1993, Annals of Internal Medicine.

[28]  D. Raccah,et al.  Plasminogen Activator Inhibitor Activity in Various Types of Endogenous Hypertriglyceridemia , 1993 .

[29]  C. Barbagallo,et al.  Effects of gemfibrozil in hyperlipidemic patients with or without diabetes , 1993 .

[30]  M. Laakso,et al.  Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia , 1992, Clinical pharmacology and therapeutics.

[31]  G. Ranelli,et al.  Effect of gemfibrozil treatment on fibrinolysis system in patients with hypertriglyceridemia , 1992 .

[32]  D. Jabs,et al.  Ocular Microvasculopathy after Bone Marrow Transplantation , 1992, Annals of Internal Medicine.

[33]  K. Bauer,et al.  Gemfibrozil Reduces Plasma Prothrombin Fragment F1+2 Concentration, a Marker of Coagulability, in Patients with Coronary Heart Disease , 1992, Thrombosis and Haemostasis.

[34]  B. Sobel,et al.  Direct Effects of Gemfibrozil on the Fibrinolytic System: Diminution of Synthesis of Plasminogen Activator Inhibitor Type 1 , 1992, Circulation.

[35]  Vesa Manninen,et al.  Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment , 1992, Circulation.

[36]  W. Haire.  Gemfibrozil predictably lowers triglycerides but does not significantly change plasminogen activator inhibitor activity in hypertriglyceridemic patients with a history of thrombosis. , 1991, Thrombosis research.

[37]  G. Steiner.  Altering Triglyceride Concentrations Changes Insulin-Glucose Relationships in Hypertriglyceridemic Patients: Double-Blind Study With Gemfibrozil With Implications for Atherosclerosis , 1991, Diabetes Care.

[38]  P. Durrington,et al.  Double‐blind Placebo‐controlled Study of the Effects of Bezafibrate on Blood Lipids, Lipoproteins, and Fibrinogen in Hyperlipidaemic Type 1 Diabetes Mellitus , 1990, Diabetic medicine : a journal of the British Diabetic Association.

[39]  C. Sirtori,et al.  Effects of lipid lowering agents and other treatment regimens on serum lipoproteins , 1990 .

[40]  H. Arnesen,et al.  Effects of Gemfibrozil on Lipids and Haemostasis after Myocardial Infarction , 1990, Thrombosis and Haemostasis.

[41]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[42]  M. Alessi,et al.  Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects , 1987, Thrombosis and Haemostasis.

[43]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[44]  T. Kjellström,et al.  The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. , 1986, Atherosclerosis.

[45]  N. Rifai,et al.  Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum. , 1986, Clinical chemistry.

[46]  T. Meade,et al.  HYPERTRIGLYCERIDAEMIA AND HYPERCOAGULABILITY , 1983, The Lancet.

[47]  J. Albers,et al.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. , 1982, Clinical chemistry.

[48]  C. Mondon,et al.  Enhanced skeletal muscle insulin sensitivity in year-old rats adapted to hypergravity. , 1981, The American journal of physiology.

[49]  Oxon Dm.  Obituary. Rupert Samuel Bruce Pearson. , 1974 .

[50]  G Bucolo,et al.  Quantitative determination of serum triglycerides by the use of enzymes. , 1973, Clinical chemistry.

[51]  D. Wilmore,et al.  Fat boys get burned. , 1972, Lancet.

[52]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[53]  S. Epstein,et al.  Impaired fibrinolytic response to exercise in patients with type-IV hyperlipoproteinaemia. , 1970, Lancet.

[54]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[55]  D. Loskutoff,et al.  The adipocyte and hemostatic balance in obesity: studies of PAI-1. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[56]  J. Kastelein,et al.  Effects of Gemfibrozil and Ciprofibrate on Plasma Levels of Tissue-type Plasminogen Activator, Plasminogen Activator Inhibitor-1 and Fibrinogen in Hyperlipidaemic Patients , 1997, Thrombosis and Haemostasis.

[57]  A. Hofman,et al.  Seasonal Variation in Fibrinogen in the Rotterdam Study , 1997, Thrombosis and Haemostasis.

[58]  A. Basdevant,et al.  Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[59]  D. Keber,et al.  The decrease of plasminogen activator inhibitor after normalization of triglycerides during treatment with fibrates , 1994 .

[60]  G. Assmann,et al.  Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[61]  L. Mannucci,et al.  Hypertriglyceridemia and regulation of fibrinolytic activity. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[62]  D. Mikhailidis,et al.  Bezafibrate Retard in Type II Diabetic Patients: Effects on Hemostasis and Glucose Homeostasis , 1990, Journal of cardiovascular pharmacology.

[63]  R. Lepore,et al.  Effect of gemfibrozil treatment on glucose tolerance in hypertriglyceridemic patients with normal or impaired glucose tolerance , 1990 .

[64]  G. Franceschini,et al.  Effects of fibrates on serum lipids and atherosclerosis. , 1988, Pharmacology & therapeutics.

[65]  P. Röschlau,et al.  Enzymatische Bestimmung des Gesamt-Cholesterins im Serum , 1974 .

[66]  D. Mackay.  Letter: Haemorrhagic syndrome of Altamira. , 1974, Lancet.